A phase I trial of TNF [tumour necrosis factor]-bound colloidal gold (CYT-6091) by intravenous administration in subjects with advanced solid organ malignancies.

Trial Profile

A phase I trial of TNF [tumour necrosis factor]-bound colloidal gold (CYT-6091) by intravenous administration in subjects with advanced solid organ malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2012

At a glance

  • Drugs CYT 6091 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 14 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 12 May 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top